(B) The report delivers a comprehensive analysis of global, regional, and country-level Mesalamine market revenues, extending projections until 2030. This dataset empowers companies to gauge their ...
To induce remission in active, mild-to-moderate ulcerative colitis. Mesalamine is an anti-inflammatory agent that is commonly used as a treatment for the induction of remission in patients with ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results